Elastography as a predictor of liver cirrhosis complications after hepatitis C virus eradication in the era of direct-acting antivirals

Table 1 Liver stiffness improvement after treatment with direct acting antivirals

Ref.	Study design	Number of Patients	Drugs	Patients with LS improvement (%)	Pre-treatment LS	Post-treatment LS	P value	Measurement
Elsharkawy et al[26], 2017	Retrospective	337	DAA	81.8% (cirrhotic) 71.7% (non-cirrhotic)	14.8 ± 10.7 kPa	11.8 ± 8.8 kPa	0.000	Fibroscan
Chekuri et al[27], 2016	Observational	100	IFN-based and DAA	NA	10.40 kPa	7.60 kPa	< 0.01	Fibroscan
Bachofner et al[30], 2017	Multicenter, observational	392	DAA	93%	12.65 kPa	8.55 kPa	< 0.001	Fibroscan
Afdhal et al[39], 2017	Prospective	52	DAA	59.6%	15.2 kPa	9.3 kPa (6.7–16.8 kPa)	< 0.0001	Fibroscan
Ravaioli et al[68], 2018	Retrospective	139	DAA	44.6% (LS reduction > 30%)	18.6 kPa (15-26.3 kPa)	13.8 kPa (10.4-20.4 kPa)	< 0.001	Fibroscan
Pan et al[70], 2018	Retrospective	84	DAA	62%	Fibrosis regression by at least two stages: Cirrhosis group (48%); F3 fibrosis group (39%)		-	Fibroscan

DAA: Direct acting antivirals; IFN: Interferon; LS: Liver stiffness; NA: Not applicable.